ADC Therapeutics SA Common Shares (ADCT)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at ADC Therapeutics at $1.70 as of 2026-10-13, with a $217.0M market cap, I see a commercial biotech whose flagship ZYNLONTA has approvals in the U.S., EU, and China, but whose financials show a business still searching for durability. In the fiscal year ended 2025-12-31, revenue was $81.4M and net loss was $142.6M, or EPS -$1.12. That improved from the fiscal year ended 2024-12-31, when revenue was $70.8M and net loss was $157.8M, or EPS -$1.62, but the company still burned a great deal of money. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $18.6M and net loss was $16.6M, or EPS -$0.11; that loss is much smaller than fiscal Q2 2025, the quarter ended 2025-06-30, when net loss was $56.6M, or EPS -$0.50. Still, trailing free cash flow is -$102.3M, a -47.1% FCF yield against the market cap, per FairStock. The Piotroski F-Score is 3/9 and Altman Z-Score is -7.64, so the fundamental and balance-sheet signals are distressed. FairStock calculations put the P/E at -2.83 and ROCE at -19.57%; P/B is N/A, so I cannot lean on book value as a backstop from this data. A wide moat is not evident; the company depends heavily on one flagship approved product with limited revenue scale and a high beta of 1.86. The stock may be a lottery ticket on clinical or commercial success, but Graham-style value requires a margin of safety from earnings, assets, or cash flow, and I do not see that here. Growth is modest and profitability remains the key hurdle.

In plain English: ADC Therapeutics is a small healthcare company that makes a targeted cancer medicine called ZYNLONTA for a type of lymphoma. The business is not yet profitable, has lost money for years, and spends more cash than it brings in, so its finances look weak. At $1.70 a share, the price may look low, but because there are no real profits to value it against, it does not look clearly cheap based on the numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer